NASDAQ:NEXI NexImmune (NEXI) Stock Price, News & Analysis $0.24 +0.03 (+14.29%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About NexImmune Stock (NASDAQ:NEXI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NexImmune alerts:Sign Up Key Stats Today's Range$0.21▼$0.2450-Day Range$0.20▼$0.3852-Week Range$0.20▼$28.69Volume5,015 shsAverage Volume2,127 shsMarket Capitalization$333,600.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Read More… Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Receive NEXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter. Email Address NEXI Stock News HeadlinesNexImmune (NASDAQ:NEXI) Stock Price Down 17.8% - What's Next?November 20 at 1:59 AM | americanbankingnews.comShattuck Labs stock craters following pipeline and job cutsOctober 3, 2024 | msn.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…November 21, 2024 | Colonial Metals (Ad)NexImmune moves forward with wind-down processAugust 31, 2024 | bizjournals.comNexImmune adjourns special meeting to explore optionsAugust 4, 2024 | investing.comNEXI Stock Alert: NexImmune Delists From NasdaqJuly 12, 2024 | investorplace.comWhat Is Going on With NexImmune (NEXI) Stock Today?July 11, 2024 | investorplace.comNexImmune, Inc. Common Stock (NEXI) After-HoursMay 26, 2024 | nasdaq.comSee More Headlines NEXI Stock Analysis - Frequently Asked Questions How have NEXI shares performed this year? NexImmune's stock was trading at $2.22 at the beginning of 2024. Since then, NEXI shares have decreased by 89.2% and is now trading at $0.24. View the best growth stocks for 2024 here. How were NexImmune's earnings last quarter? NexImmune, Inc. (NASDAQ:NEXI) posted its quarterly earnings data on Friday, November, 12th. The company reported ($16.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($16.75) by $0.50. When did NexImmune's stock split? NexImmune shares reverse split on the morning of Thursday, October 19th 2023. The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did NexImmune IPO? NexImmune (NEXI) raised $75 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. acted as the underwriters for the IPO. How do I buy shares of NexImmune? Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NexImmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that NexImmune investors own include Athenex (ATNX), Achilles Therapeutics (ACHL), TherapeuticsMD (TXMD), Bolt Biotherapeutics (BOLT), KLX Energy Services (KLXE), Lannett (LCI) and Exela Technologies (XELA). Company Calendar Last Earnings11/12/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NEXI CUSIPN/A CIK1538210 Webwww.neximmune.com Phone301-825-9810FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($18.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-534.32% Return on Assets-213.72% Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book0.07Miscellaneous Outstanding Shares1,395,000Free Float1,187,000Market Cap$334,800.00 OptionableNot Optionable Beta1.66 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:NEXI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.